New table highlighting results in IMDC favorable risk RCC across IO-based doublets and nivo/pembro monotx trials. Major caveats about small subsets and differing follow-up, but interesting observations emerge. Thanks to Toni Choueiri, MD and Mike Atkins for help assembling data.

Thank you to Canadian Association of Medical Oncologists leadership. This is truly an honour — with so many worthy candidates in their first 10 yrs of career. Grateful for collaborative colleagues and guiding mentors (near and far) for their ongoing support along my path! 🙏 👏 B. Dhesy-Thind Sharlene Gill, MD, MPH, MBA, FASCO CAMOPREZ

1/ Results from #COSMIC-313 are out NEJM: 1st triplet combo (cabo/nivo/ipi) in #mRCC vs. a modern control (nivo/ipi). Initially presented as Plenary #ESMO22 session chaired by Charles Swanton Andres Cervantes #ESMO22 Thread 🧵==> nejm.org/doi/full/10.10…

Thank you to our Site Investigators, Site Staff and Supporters for making CKCis such a success! #OperationsCommittee #CKCis #KidneyCancer #CanadianData Rod Breau Naveen Basappa, MD Simon Tanguay Rahul Bansal Daniel Heng Aly-Khan Lalani Jay Nayak Bimal Bhindi Tony Finelli

On June 23, at the CUA Mtg. in Montreal, Dr. Armen Aprikian announced the re-naming of the CUASF - KCRNC Kidney Cancer Cancer Research Grant as The Anil Kapoor Kidney Cancer Research Grant in memory of his leadership & support of kidney cancer research. #CUA23 Kidney Cancer Canada

Thank you to the Canadian Urological Association and Kidney Cancer Canada for honouring the memory of Dr. Anil Kapoor through the renaming of a kidney cancer research grant. Dr. Kapoor is remembered as a skilled surgeon, an exceptional researcher, and a healer. #urology St. Joe's Healthcare (Hospital & Foundation) McMaster Health Sciences

Kidney Cancer Canada is hosting an in-person information session at St. Joe's Healthcare (Hospital & Foundation) in Ontario. This session will focus on adjuvant treatment with #kidneycancer specialists Rahul Bansal and Aly-Khan Lalani kidneycancercanada.ca/news/in-person…

Enfortumab vedotin & Pembrolizumab improving PFS & OS by 55% & 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%). Chemo has not been beaten before (despite multiple efforts). RR and CR of 68% & 29% is hard to beat. DOR not reached (1/3)#ESMO2023

Check out the CR rate 29%, benefit no matter PDL1 status or cisplatin eligibility. OS 0.47. #bladdercancer first line has now officially changed. OncoAlert #ESMO23 Tom Powles I’m so proud of you. #standingovation.

This is what we are looking for: OS benefit! I wonder what the HR will be. Adjuvant #kidneycancer IKCC Kidney Cancer OncoAlert I’m seeing three patients this Friday for adjuvant pembro.

Anil Kapoor was a gifted surgeon with a bedside manner that put everyone at ease theglobeandmail.com/life/article-a…

Tragic case of fatal #5FU toxicity - grateful that Dr. Anil Kapoor’s family has taken this issue public. CBC News: The National Hopefully will push resources for routine DPYD screening 🇨🇦 ➡️BC Cancer adopted DPYD testing in BC last year🙏 ➡️ we need to learn more about variants in

A big day for bladder ca patients U.S. FDA. Massive team effort. Platinum based chemo superseded at last. EV/pembro will transform the lives of many pts with this difficult disease. Still lots to do but it’s a pretty good day and worth pausing for a moment. bit.ly/3GLntQn

Enfortumab Vedotin + pembro shows broad spectrum of activity for RR PFS and OS in all subgroups. This includes subsets such as lymph node disease, liver mets, PD-L1 status, upper tract disease, platinum eligibility. This +ve data underlines EVP as a new standard of care #GU24

Adjuvant pembro ⬆️ DFS (0.69) but ❌ OS (0.98) in UC, ~10% tox ++. Atezo also had ❌ OS. Nivo had 0.7 DFS but no OS data after ++ years-assuming it’s +ve seems unwise. Without OS we’re over treating. Adjuvant IO in all comers is on shaky ground without more data IMO #GU24

Another great #CKCis OC meeting at #CKCF24. Thank you to all of our sites for their continued hard effort and to our supporters! #kidneycancer #registry #Canadian Naveen Basappa, MD Rod Breau Simon Tanguay Rahul Bansal Robert Bick Tony Finelli Jeffrey Graham

A touching tribute to the imitable Dr. Anil Kapoor at #CKCF24 . A remarkable mentor, urologist and one of the kindest, and most witty people in any room. He will be dearly missed and has forever left a legacy in the world of #RCC . Canadian Urological Association

The final results of #POUT adjuvant trial in Upper Tract Urothelial cancer (UTUC) adjuvant trial are now published in Journal of Clinical Oncology. This is a landmark study in the field and 💙alison birtle + team should be celebrated. 5-year DFS (1EP): 62% vs. 45%, HR 0.55 (95% CI, 0.38-0.80,

Adjuvant pembrolizumab shows a significant and clinically meaningful OS benefit in intermediate and high risk clear cell renal cancer for the 1st time (KN564). This further tips the balance towards giving adjuvant pembro in this setting NEJM Toni Choueiri, MD nejm.org/doi/full/10.10…

1/ The long-awaited OS results from #KEYNOTE-564 are out NEJM! The 1st phase 3 trial to demonstrate a survival benefit for adjuvant treatment in #RCC. nejm.org/doi/full/10.10…